Program Research Highlights:
-
Studies defining the impact of hemodynamic response to medical therapy
on clinical outcomes in advanced heart failure;
-
Demonstration that a comprehensive disease management program for
advanced heart failure improves clinical outcomes and lowers medical
costs as compared to conventional care;
-
Discovery that the degree of ventricular remodeling predicts mortality
in patients with heart failure independently of other pathophysiological
factors;
-
Definition of diverse mechanisms and risk factors for sudden death in
advanced heart failure including syncope and type I antiarrhythmic
agents;
-
Research into the role of positron emission tomography (PET) in guiding
revascularization in advanced ischemic cardiomyopathy;
-
Findings showing that HMG CoA Reductase inhibitors (statins) reduce
rejection and prolong patient survival, post heart transplantation;
-
First observations study showing that statins are associated with lower
mortality risk in patients with heart failure, irrespective of etiology
-
Comparison of quality of life in patients with heart failure treated
with sustained medical therapy vs. cardiac transplantation;
-
Impact of cardiac rehabilitation in patients’ post cardiac
transplantation;
-
Development of a program to ensure that patients hospitalized with
cardiovascular disease are initiated on therapies able to reduce the
risk of recurrent cardiac events, heart failure, and mortality. This
Program called CHAMP
(Cardiovascular Hospitalization Atherosclerosis Management Program) has
received national attention, and the American Heart Association has
modeled a program based on CHAMP called Get With The Guidelines that
will be implemented nationwide.
- First
simple bedside tool to predict mortality risk in patients hospitalized
with heart failure
|
